Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclacumab for prevention of vaso-occlusive crises in sickle cell disease
PACTR202106511293049Phase 3Recruiting
- Sponsor
- Global Blood Therapeutics
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Inclacumab IV with Placebo IV (2 arms). Primary endpoint: Rate of vaso-occlusive crises during 48-week treatment period. Started Jun 2021; status: recruiting.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202106511293049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106511293049.